[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: First name + initial]
[Robert: month year of review]
Authentic Tirzepatide from Eli Lilly — Mounjaro for diabetes, Zepbound for weight management. Cold-chain delivery across Thailand. International patients travel to our Pattaya clinic; Singapore monthly courier.
That's −17.8 kg — you'd weigh .
Based on the 20.9% trial-mean. Individual outcomes vary.
Licensed medical facility · Real photos · Dr. Kenika
Tirzepatide is the first medicine that activates two gut-derived hormone receptors simultaneously — GIP and GLP-1. This dual mechanism produces stronger appetite regulation and metabolic effects than single-pathway GLP-1 medicines like Semaglutide. The molecule is manufactured by Eli Lilly and is marketed under two brand names depending on indication.
Slows gastric emptying, suppresses appetite, improves insulin response after meals. The same pathway as Semaglutide (Wegovy, Ozempic), but Tirzepatide engages it alongside a second receptor.
Improves fat metabolism and insulin sensitivity. Tirzepatide is the first approved medicine to engage this pathway therapeutically — the addition responsible for its stronger results versus GLP-1-only agents.
Read the underlying research: SURMOUNT-1 (NEJM 2022 · Jastreboff et al.) · For the broader weight-loss medicine landscape see our Weight Loss Thailand overview.
Tirzepatide is sold under two brand names depending on regulatory indication. Both are manufactured by Eli Lilly and Company. The active molecule, dose strengths, and pen format are identical.
FDA-approved May 2022 for the treatment of Type 2 diabetes mellitus. Used widely for adults whose physicians want both blood-sugar control and weight management.
FDA-approved November 2023 for chronic weight management in adults with obesity or overweight plus weight-related comorbidities. Same Tirzepatide molecule, different labeled indication.
Pricing for Mounjaro and Zepbound is discussed during your private consultation. Thai pharmacy advertising regulations preclude listing exact figures online.
Doctor-led · Authentic Eli Lilly · Mounjaro / Zepbound
↑ Take-home pens available from 16,990 ฿/month
Tirzepatide is dispensed as Mounjaro (Type 2 diabetes) or Zepbound (chronic weight management) — pharmacologically identical KwikPens® from Eli Lilly. Same molecule, indication-specific labels.
Per-shot pricing at higher doses confirmed during your consultation. Final program pricing depends on your dose plan and treatment duration. Thai pharmacy advertising regulations preclude binding online prices — your exact figure is shared in private medical review.
Three weekly injectable medicines, each at a different stage of development and pharmacological complexity.
| Dimension | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Average weight loss | 15-17% (STEP-1) | 20-22% (SURMOUNT-1) | 24%+ (TRIUMPH Phase 3) |
| Receptor pathways | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| FDA status | Approved · Wegovy (2021), Ozempic (2017) | Approved · Mounjaro (2022), Zepbound (2023) | Phase 3 complete · approval anticipated |
| Dosing | Weekly subcutaneous | Weekly subcutaneous | Weekly subcutaneous |
| Common brand(s) | Wegovy, Ozempic (Novo Nordisk) | Mounjaro, Zepbound (Eli Lilly) | No brand yet — specialty |
| Best fit for | First-time GLP-1 patients, lower BMI | Patients seeking stronger results than GLP-1 alone | Highest BMI, prior GLP-1 plateau, latest research |
Dr. Kenika reviews your medical history, BMI, comorbidities, and prior treatment history to recommend the right choice for you.
Trajectory based on the SURMOUNT-1 clinical-trial mean. Your individualized program is confirmed in consultation — this is an evidence-based estimate, not a guarantee.
Your trajectory · based on SURMOUNT-1 mean (Tirzepatide)
Estimator uses peer-reviewed clinical-trial mean data. Individual outcomes vary based on adherence, baseline BMI, comorbidities, and lifestyle factors. Final program plan determined in private medical consultation.[ref]
Tirzepatide follows the manufacturer titration schedule — incremental dose increases minimize gastrointestinal side effects and allow your body to adapt to the appetite-suppressing effect.
Source: Eli Lilly Mounjaro & Zepbound prescribing information. Adapted individually based on tolerance and response.
15-minute WhatsApp with our clinic team. Share your goals, history, and questions. No commitment.
Dr. Kenika reviews your history. Labs ordered if needed. Treatment plan decided based on your specific clinical picture.
First dose at clinic or cold-chain delivery to your address. Titration plan + side-effect support from day one.
Weekly check-ins during titration. Dose adjusted to your response. Sustainable maintenance plan together.
Every Tirzepatide patient is personally supervised by Dr. Kenika — medical history review, HbA1c monitoring where relevant, dose decisions, titration adjustments. No intake-form-only approval.
Authentic Tirzepatide from Eli Lilly via cold-chain pharmacy distribution. Batch numbers and expiry dates intact. No compounded substitutes, no grey-market sourcing.
In-clinic in Pattaya, concierge nurse to your hotel in Bangkok, or online consultation with cold-chain delivery in Phuket and beyond.
More questions? See the Weight Loss Thailand FAQ or message us directly on WhatsApp.
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing. Updating list is syncing automatically (Phase 2 integration).
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
Request a consultation. Our clinic team responds within minutes on WhatsApp and walks you through the next steps — review of your medical history, dose plan, sourcing, and the access mode that fits your location.
Request consultation
Peer-reviewed primary sources, FDA prescribing information, and manufacturer documentation.
Additional clinical questions are discussed during your private consultation with Dr. Kenika.
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Dual GIP/GLP-1 receptor agonist. Highest trial-mean of any approved GLP-1 medicine.
See program →
Most-prescribed GLP-1 in clinical practice. Excellent track record for goals up to 15%.
See program →
Investigational GLP-1/GIP/Glucagon triple agonist. Highest documented mean reduction in incretin trials.
See program →
In-person consultation, baseline labs, same-week start. Walk-in friendly.
See program →